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Connective tissue turnover plays a prominent role in tumour growth and metastasis. We followed serum levels of seven connective
tissue parameters in 37 patients with colorectal cancer metastatic to the liver prior to and during chemotherapy. Serum samples with
episodes of tumour control (n¼112) showed an increase of matrix metalloproteinase-2 (MMP-2) (Pp0.01) and a decrease of tissue
inhibitor of MMPs (TIMP-1) levels (Pp0.01), while serum samples with episodes of tumour progression displayed the reverse pattern
(Pp0.01 and Pp0.05, resp.). The ratio of circulating MMP-2/TIMP-1 was also significantly higher in episodes of tumour control vs
tumour progression and prior to treatment (Pp0.0001). We conclude that serum MMP-2 appears to reflect tumour resorption,
while serum TIMP-1 may mirror tumour expansion.
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Matrix metalloproteinases (MMPs) are proteolytic enzymes that
play a central role in benign and malignant matrix remodelling
(Ka ¨ha ¨ri and Saarialho-Kere, 1999; Nagase and Woessner, 1999).
MMP-2 and MMP-9 (gelatinases A and B, resp.) degrade basement
membrane collagen as well as denatured collagens (gelatin). MMP
activity is tightly regulated (1) on the level of transcription, (2) on
the level of proteolytic activation of the pro-MMPs, (3) by the
tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) and
(4) by their strict compartmentalisation in cell membrane
domains. Enhanced local expression and activity of MMPs and
low levels of inhibitory TIMPs correlate with tumour growth and
metastasis (Zeng et al, 1995, 1996; Murray et al, 1996). However,
the findings on circulating MMP- and TIMP levels in patients with
metastatic colorectal tumours are unclear (Holten-Andersen et al,
2000; Pellegrini et al, 2000; Ylisirnio et al, 2000).
CEA and CA 19-9 have been previously shown to predict tumour
growth in patients with liver metastasis treated by chemotherapy
(Hanke et al, 2001). However, there exist no follow-up data with
serum connective tissue markers to predict treatment response
or nonresponse in these patients. Colorectal cancer metastatic to
the liver is particularly suited to validate novel markers, since
the condition is characterised by a large and defined tumour
burden.
MATERIALS AND METHODS
We studied 37 consecutive patients (29 men, eight women, age 42–
76 years, mean 62 years) with colorectal carcinoma metastatic to
the liver. Primary carcinoma was confirmed histologically.
Histological confirmation was also obtained for synchronous liver
metastasis. In case of metachronous liver metastasis, histological
confirmation was only pursued when imaging techniques (spiral
computerised tomography (CT) of the abdomen or MRT of the
liver) did not show clear results. Patients received first-line
chemotherapy, consisting of a weekly 1–2h infusion of folinic
acid (500mgm
 2) followed by a 24-h infusion of 5-fluorouracil
(2600mgm
 2). One cycle comprised six weekly infusions followed
by 2 weeks of rest. A total of 16 patients received additional
biweekly oxaliplatin (85mgm
 2) and three patients additional
weekly irinotecan (80mgm
 2) (Wein et al, 2001, 2003). Treatment
response was monitored every 8 weeks by spiral CT and
antitumour activity was evaluated in accordance with WHO
criteria. Median treatment duration was 7 months. Patients were
stratified as ‘prior to treatment’, ‘tumour control’ (complete/partial
remission or stable disease) and ‘tumour progression’. In 23 of 37
patients, first serum was obtained immediately prior to treatment.
In all 37 patients, we recorded 112 episodes of tumour control, and
in 16 of 37 patients we recorded episodes of tumour progression.
The patients had been treated within the framework of two clinical
phase II studies after obtaining approval by the local ethics
committee (Wein et al, 2001, 2003).
Sera were obtained at 8 weekly intervals, along with CT, stored
frozen at  801C and analysed for six circulating connective tissue
markers in a single run. Serum collagen IV and VI, tenascin-C,
MMP-2, the MMP-9/TIMP-1 complex and free TIMP-1 were
measured on the Bayer Immuno 1t Analyzer using fluorescein-
and alkaline-phosphatase-labelled monoclonal antibodies to the
target antigen (Schuppan et al, 1995; Ropers et al, 2000). Immune
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ycomplexes were separated with magnetic particles coated with a
monoclonal antifluorescein antibody and quantified after substrate
addition. Analysis was restricted to MMP-2 and TIMP-1 (repre-
senting both the free and the bound protein), since only these
markers correlated well with tumour evolution. Normal values for
100 healthy adults were 641ngml
 1 (s.d. 5.5%) for MMP-2 and
620ngml
 1 (s.d. 4.9%) for TIMP-1.
For descriptive analysis all sera referring to ‘prior to treatment’,
‘tumour control’ and ‘tumour progression’ were grouped together.
For confirmatory analysis, values were averaged for each patient to
yield only one value per category. With only four of the patients
who contributed values for initial tumour status showing
progression, confirmatory analysis was restricted to the compar-
ison of ‘prior to treatment vs tumour control’ and ‘progression vs
tumour control’. Comparisons were performed using the Wilcoxon
test for paired samples. P-values were multiplied by two according
to Bonferroni’s correction for multiple testing. The level of
significance was 0.05 (two-sided). All analyses were performed
using SPSSWIN 9.0.
RESULTS
A total of 37 patients received systemic chemotherapy during an
average treatment duration of 7 months. Prior to treatment, serum
TIMP-1 was elevated (42s.d. above the normal mean) in 57% (13
out of 23), decreasing to 36% (40 out of 112) in episodes with
tumour control and increasing to 81% (13 out of 16) in episodes
with progression (Po0.01 and Po0.05, resp.). Serum MMP-2 was
elevated in 9% (two out of 23) prior to treatment, increasing to
35% (40 out of 112) in tumour control and decreasing to 12% (two
out of 16) with progression (both differences Po0.01, see Table 1).
The ratio MMP-2/TIMP-1 differed significantly between episodes
and ranged from 0.73 ‘prior to treatment’, increasing to 1.12 under
tumour control and decreasing to 0.71 upon tumour progression
(Pp0.001) (Figure 1).
DISCUSSION
This is the first report of the course of serum connective tissue
markers in patients undergoing chemotherapy for colorectal
carcinoma metastatic to the liver. Among the six tested markers,
only MMP-2 and TIMP-1 correlated with the response to
chemotherapy. Changes in elimination do not explain the
differences in MMP and TIMP-1 serum levels, since during
chemotherapy both serum creatinine and parameters of cholestasis
remained unaltered.
Table 1 Numerical values of serum MMP-2/TIMP-1 in patients with metastatic colorectal cancer prior to and during chemotherapy
MMP-2 (ngml
 1) TIMP-1 (ngml
 1) MMP-2/TIMP-1
Mean Median s.d. Range Mean Median s.d. Range Mean Median s.d. Range
Prechemotherapy 670** 599 225 442–1439 956** 934 230 605–1318 0.73*** 0.73 0.25 0.35–1.30
Tumour control 861 827 199 492–1396 808 752 228 454–1556 1.12 1.09 0.32 0.46–1.90
Tumour progress 744** 779 178 534–1130 1155* 1062 395 665–1949 0.71*** 0.62 0.31 0.29–1.42
Levels of significance compared with tumour control: *Pp0.05, **Pp0.01, ***Pp0.001. Normal values: MMP-2 620ngml
 1 (s.d. 4.9%), TIMP-1 641ngml
 1 (s.d. 5.5%).
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Figure 1 Ratio of circulating serum MMP-2/TIMP-1 in patients with metastatic colorectal cancer prior to and during chemotherapy. Circles correspond to
extreme values in the statistical analysis. Total numbers of episodes¼N (box plot analysis). Levels of significance compared with tumour control: *Pp0.05,
**Pp0.01, ***Pp0.001.
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yThe increase of MMP-2 and the decrease of TIMP-1 under
tumour control is unexpected, since a common assumption is that
enhanced activity of MMP-2, the classical basement membrane
collagenase, leads to tumour growth and metastasis, while TIMP-1
as a crucial inhibitor of many MMPs should rather curtail tumour
expansion (Nagase and Woessner, 1999). However, it remains to be
proven if and how far tumour growth, which is accompanied by a
strictly local control of proteolysis, leads to an excessive release of
the involved enzymes or inhibitors (MMPs and TIMPs). Alter-
natively, an enhanced release of MMP-2, an enzyme which is
sequestered on the cell surface and on collagens in the matrix, can
be expected when the tumour volume and the associated
desmoplastic stroma are reduced under effective chemotherapy.
In addition, with enhanced resorption of tumour stroma, free
TIMP-1 may be consumed by the various MMPs implicated in this
process. The latter interpretation is in line with two cross-sectional
studies in patients with advanced pulmonary and colorectal
cancer, which showed elevated serum levels in tumours that
progressed rapidly (Holten-Andersen et al, 2000; Pellegrini et al,
2000).
Therefore, therapies of advanced tumours that are based on
unselective MMP inhibitors as a supplement to chemotherapy may
be of little use, if not counterproductive. This assumption is
supported by the disappointing outcome of several recent clinical
studies using such agents (Bramhall et al, 2001; Coussens et al,
2002; Shepherd et al, 2002).
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